AstraZeneca
NEWS
AstraZeneca and Daiichi Sankyo presented positive data from their Phase II single-arm DESTINY-Breast01 trial of trastuzumab deruxtecan (DS-8201) in HER2-positive metastatic breast cancer patients who received two or more previous HER-2 targeted regimens.
As the 61st American Society of Hematology Annual Meeting wrapped up in Orlando, Florida, there were hundreds of studies and results presented. Here’s a look at some.
AstraZeneca released new data that shows Calquence as a monotherapy and combined with Roche’s anti-CD20 drug Gazyva significantly improved progression-free survival in previously untreated CLL.
AstraZeneca inked a deal with Germany-based Cheplapharm Arzneimittel GmbH to sell the commercial rights to Seroquel and Seroquel XR in the U.S. and Canada.
While there is no cure for the disease, there are a number of drugs that have been approved to treat the illness. And with the growing number of cases, the drug market for COPD is expected to dramatically increase as well.
The so-called “heart-in-a-jar” will be created from human stem cells and designed to reproduce key phenotypic characteristics of heart failure.
Effective treatments for diabetes are becoming more and necessary. The past few years have demonstrated productive strides in drug therapies, such as following medications.
As usual, it was a busy week for clinical trial updates. Here’s a look.
The latest approval for Calquence, a Bruton tyrosine kinase inhibitor, was granted under the FDA’s Real-Time Oncology Review and newly established Project Orbis programs.
JOBS
IN THE PRESS